Why patients come first

Learn More

Synageva is committed to meeting the needs of the rare disease community. That’s why we rely on the voice of the patient as our decision-making guide.

Meet the team and discover our history

Learn More

We are passionate about our commitment to improving the lives of patients with rare diseases for generations to come.

Relentless dedication towards R&D and our pipeline

Learn More

Our strategy is to discover, develop and deliver medicines that make a meaningful impact on the lives of patients.

It takes uncommon courage to live with a rare disease – our goal is to make a meaningful impact on the lives of patients with our inspiration, drive, energy and passion.

Synageva BioPharma is dedicated to discovering, developing and delivering therapies for patients with rare conditions and unmet medical needs.

The hope and dedication of the patients and their families is what drives us each and every day, hour, minute and second.”

Sanj K. Patel

President, Chief Executive Officer & Director

Recent News and Events

Synageva BioPharma Reports 2014 Full Year Financial Results

February 26, 2015 - Lexington, MA

Synageva BioPharma To Present At The Cowen and Company Health Care Conference

February 25, 2015 - Lexington, MA

FDA Accepts BLA Filing For Synageva's Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date

February 23, 2015 - Lexington, MA

Synageva BioPharma To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26

February 19, 2015 - Lexington, MA

Read More

Synageva's employees share a passion and commitment for improving the lives of patients with rare diseases.”

Robert Bazemore

Chief Operating Officer

Building the Pipeline

Preclinical
Phase 1/2
Phase 3
BLA/MAA
Under Review
Sebelipase Alfa (LAL Deficiency)
BLA/MAA
BLA/MAA
BLA/MAA
BLA/MAA
SBC-103 (MPS IIIB)
Phase 1/2
Phase 1/2
SBC-105 (GACI/other)
Pre-Clinical
Bio-superiors
Pre-Clinical
SBC-104 (Undisclosed)
Pre-Clinical
SBC-106 (Undisclosed)
Pre-Clinical
SBC-342 (Undisclosed)
Pre-Clinical

Learn More

We want to make therapies that make a difference.”

Anthony G. Quinn MD, PhD FRCP

Executive Vice President
Chief Medical Officer & Head of R&D

Rare diseases are not that rare

7000+ distinct rare diseases